Background
• The Agency for Care Effectiveness (ACE) was established in 2015 to expand health technology assessment (HTA) capabilities for subsidy decisions in Singapore. 1 • The Singapore Ministry of Health (MOH) provides subsidies for drugs under the Standard Drug Lists (SDL 1 and 2) and the Medication Assistance Fund (MAF). Most SDL drugs are capped at S$1.40 per week for subsidised patients, while higher cost SDL and MAF drugs are subsidised at 50% or 75% of the retail price.
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Methods
• The 14 appraisals published by ACE in 2017 (May and October) were reviewed.
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• For each appraisal, the type of evaluation (full or expedited), subsidy recommendation, and factors that were considered by the MOH Drug Advisory Committee (DAC) to inform subsidy recommendation were recorded.
• Further information on ACE's drug evaluation methods and processes were obtained at the ACE Industry Briefing held in May 2017.
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Results
• Out of the 14 appraisals of 19 drugs, 5 led to subsidy listing on the SDL 1 or 2, 7 led to inclusion in the MAF, and 2 led to no subsidy.
• 13 evaluations were expedited evaluations as they were generics or had a low budget impact, with trastuzumab being the only therapy that was considered in a full evaluation due to its high cost.
-In full evaluations, manufacturers must submit their proposed price and may be invited to submit clinical and economic data. ACE will also conduct a review of available clinical and economic data, and will develop local cost-utility and budget impact models.
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-In expedited evaluations, manufacturers must submit their proposed price and ACE will review published clinical and economic evidence, and will develop a local budget impact model.
• The factors that influenced subsidy decisions are summarised in Table 1 .
• Three of the subsidised drugs (somatropin, trastuzumab and Botox ® ) were in areas of substantial clinical need. In the absence of clinical need, the price relative to existing alternatives appeared to be a key consideration: compared to other subsidised anti-TNFs, golimumab was cost-effective at the manufacturer's proposed price but ustekinumab was not, as its price was higher than existing subsidised treatments.
• In the 3 appraisals where more than 1 technology in the same class were compared, only the cheapest drug was subsidised in each case (rivaroxaban, dapagliflozin and Botox ® ), further indicating the importance of drug cost in subsidy decisions.
• In 3 appraisals (gliclazide, golimumab and trastuzumab), restrictions were imposed on the type of formulation covered by the subsidy.
-The modified-release version of gliclazide was not subsidised due to its higher cost and equivalent outcomes to the immediate-release formulations.
-Basaglar ® Kwikpen version was not subsidised as its price was higher than that of Lantus ® pen, which is currently listed on the SDL for the same indication.
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-The intravenous (IV) formulation of golimumab was not subsidised, likely to avoid additional healthcare costs associated with IV administration, although this was not specifically stated.
• Only 6 evaluations reported incremental cost-effectiveness ratios (ICERs), half were derived from UK cost-effectiveness studies while the other half were from Singaporean studies. Among Singaporean cost-effectiveness studies, an ICER of up to S$75,000 per quality-adjusted lifeyear gained was considered cost-effective. However, given the small number of appraisals reporting ICERs, no conclusions around a formal willingness-to-pay threshold can be drawn.
• Budget impact was a key consideration across all appraisals. However, both drugs that were not recommended for subsidy had a lower budget impact (below S$1 million per year) than rivaroxaban, which was subsidised despite having the highest budget impact of S$3-S$5 million per year. 
Conclusions
• This analysis highlights the importance of technology cost in HTA decisions in Singapore. In the absence of a clinical need, the price relative to treatments already subsidised appears to be a key factor in decisionmaking. The cost of different formulations was also considered for formulation-specific recommendations.
• This research was limited by the small number of appraisals and will be updated in future as further evaluation decisions are published.
Objective
• This research explored possible factors influencing health technology assessment subsidy decisions in Singapore.
AF: atrial fibrillation; AS: ankylosing spondylitis; DAC: Drug Advisory Committee; ICER: incremental cost-effectiveness ratio; NOAC: novel oral anticoagulant; PsA: psoriatric arthritis; QALY: quality-adjusted life-year; RA: rheumatoid arthritis; SGLT2: sodium-glucose co-transporter 2; TNF: tumour necrosis factor; UC: ulcerative colitis. 
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